ArticleAnnals of clinical microbiology and antimicrobials2021
Epidemiology, species distribution, and outcome of nosocomial Candida spp. bloodstream infection in Shanghai: an 11-year retrospective analysis in a tertiary care hospital.
Article in Annals of clinical microbiology and antimicrobials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial.The Journal of antimicrobial chemotherapy · 2023Trial
- Temporal changes in fungal epidemiology in ICU post-operative peritonitis cases.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Clinical characteristics and risk factors of mortality in patients with candidemia: a four-year retrospective study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Epidemiology, risk factors, and mortality of Candida bloodstream infection in Yulin, China: a 7-year retrospective study.BMC infectious diseases · 2026Article
- Epidemiology, Antifungal Susceptibility, and in-Hospital Mortality of Candidemia in a Tertiary Hospital of China: A 10-Year Retrospective Analysis.Infection and drug resistance · 2026Article
- Epidemiology, risk factors, and antifungal susceptibility analysis of Candida tropicalis and non-C.tropicalis candidemia.BMC infectious diseases · 2025Article
- Epidemiology, Risk Factors and Mortality of Fungal Bloodstream Infection: 14 Years of Experience at a Teaching Hospital.Mycopathologia · 2025Article
- Epidemiology, clinical characteristics, and outcome in candidemia: a retrospective five-year analysis from two tertiary general hospitals.BMC infectious diseases · 2025Observational
- Epidemiology and Clinical Features ofJournal of fungi (Basel, Switzerland) · 2025Article
- Molecular and biological characteristics of two rare bloodstream Candida isolates: Candida nonsorbophila and Candida sonorensis.BMC infectious diseases · 2025Article
- An 11-Year retrospective analysis of candidiasis epidemiology, risk factors, and antifungal susceptibility in a tertiary care hospital in China.Scientific reports · 2025Article
- Clinical and molecular features of candidemia: a three-year retrospective study in Northern Guizhou, China.Frontiers in cellular and infection microbiology · 2025Article
- Amphotericin B in the Era of New Antifungals: Where Will It Stand?Journal of fungi (Basel, Switzerland) · 2024Review
- Rapid identification of the predominant azole-resistant genotype in Candida tropicalis.FEMS yeast research · 2024Article
- Epidemiology and Risk Factors of Candidemia a 8-Year Retrospective Study from a Teaching Hospital in China.Infection and drug resistance · 2024Article
- Molecular diagnosis, phylogenetic analysis, and antifungal susceptibility profiles of Candida species isolated from neutropenic oncological patients.BMC infectious diseases · 2023Article
- Alarming Increase of Azole-Resistant Candida Causing Blood Stream Infections in Oncology Patients in Egypt.Current microbiology · 2023Article
- InvasiveMicroorganisms · 2023Article
- Nanotechnology-Based Approaches for Voriconazole Delivery Applied to Invasive Fungal Infections.Pharmaceutics · 2023Review
- Epidemiological Characteristics, Antifungal Susceptibility, Risk Factors, and Outcomes ofInfection and drug resistance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe incidence of Candida bloodstream infections (BSIs), has increased over time. In this study, we aimed to describe the current epidemiology of Candida BSI in a large tertiary care hospital in Shanghai and to determine the risk factors of 28-day mortality and the impact of antifungal therapy on clinical outcomes.
methodsAll consecutive adult inpatients with Candida BSI at Ruijin Hospital between January 1, 2008, and December 31, 2018, were enrolled. Underlying diseases, clinical severity, species distribution, antifungal therapy, and their impact on the outcomes were analyzed.
resultsAmong the 370 inpatients with 393 consecutive episodes of Candida BSI, the incidence of nosocomial Candida BSI was 0.39 episodes/1000 hospitalized patients. Of the 393 cases, 299 (76.1%) were treated with antifungal therapy (247 and 52 were treated with early appropriate and targeted antifungal therapy, respectively). The overall 28-day mortality rate was 28.5%, which was significantly lower in those who received early appropriate (25.5%) or targeted (23.1%) antifungal therapy than in those who did not (39.4%; P = 0.012 and P = 0.046, respectively). In multivariate Cox regression analysis, age, chronic renal failure, mechanical ventilation, and severe neutropenia were found to be independent risk factors of the 28-day mortality rate. Patients who received antifungal therapy had a lower mortality risk than did those who did not.
conclusionsThe incidence of Candida BSI has increased steadily in the past 11 years at our tertiary care hospital in Shanghai. Antifungal therapy influenced short-term survival, but no significant difference in mortality was observed between patients who received early appropriate and targeted antifungal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.